What are PTA Member Advisory Panels (MAPs)?
We regularly convene member advisory panels (MAPs) that are open to all members and relevant stakeholders. PTA believe successful delivery of healthcare requires collaboration and a shared vision. We ensure our voice represents the diversity of manufacturers, suppliers, specialized services, and infrastructure – the key providers of the tools and technology to delivery essential healthcare services.
Our Seat at the Table
Your voice and experience are represented in multiple ongoing forums.
Our advocacy informs the policies and practices that impact how member products are assessed, funded, and integrated into best practice.
Point of Care Testing
A multi-stakeholder working group was convened by the Department of Health responding to our advocacy and Ministerial directive to better utilise point-of-care testing (POCT) to address widespread inequities and unmet needs in our healthcare system.
Through ongoing MAP consultation, we will review and contribute towards the final whitepaper recommendation to be sent to the Medical Services Advisory Council (MSAC) in the first quarter of 2025. This is an opportunity to inform new processes that better support the adoption of these important healthcare tools.
![multi omics sangharsh-lohakare-8o_LkMpo8ug-unsplash[1] (2)](https://pathologytechnology.org.au/wp-content/uploads/2025/02/multi-omics-sangharsh-lohakare-8o_LkMpo8ug-unsplash1-2.jpg "multi omics sangharsh-lohakare-8o_LkMpo8ug-unsplash[1] (2)")
Genomics
PTA was selected in a government expert advisory group (EAG) tasked with scoping the purpose, priorities, and functions of a soon to be established Federal body for genomics in healthcare – Genomics Australia.
A MAP informed our voice throughout the 12-month process ending July 2024. This diverse group of members and stakeholders agreed the way this body operationalizes in collaboration with States and Territories is key. This MAP will stay active and continue to advocate for a seat at the table to advise on the critical decisions of how genomics will be integrated into Australia’s health system.
Antimicrobial Resistance
PTA are included in a CSIRO-led action group focused on antimicrobial resistance (AMR). The focus group launched a summary of their discussions in Nov 2024.
The communique outlines key priorities and policy recommendations for a consistent, evidence-based approach to optimal antimicrobial prescribing. The focus on prescribing practices in primary and community settings was chosen for this project, as these are the settings where the vast majority of human antimicrobials are prescribed.
You can view the AMR communique here. PTA will continue to advocate for targeted use of pathology technology to support antimicrobial stewardship best practice.
PTA MAP BENEFITS
Collectively our member advisory panels:
- Represent the diversity of membership views and experience.
- Inform and influence relevant government departments.
- Collaboratively respond to policy and consultation papers.
- Offer professional development through sector-wide networking.
- Receive pro-active communication on relevant updates and activities.
- Influence priorities of PTA activities.